drugset / Trial / NCT02645253

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men

NCT02645253

Phase 1 Completed 27 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindBasic science

Summary

This is a randomized, single-blind, placebo-controlled, sequential-group study to assess the safety and tolerability as well as how the drug (AZD7594) affects the body (pharmacodynamics \[PD\]) and how the body affects the drug (pharmacokinetics \[PK\]) when AZD7594 is given as single and multiple ascending doses once daily by inhalation to healthy male Japanese subjects, compared with placebo (non-active drug)

Timeline

Start
2016-01-12
Primary completion
2016-04-17
Completion
2016-04-17

Drugs

EvaluationDrugModalityDoseRoute
Subject VELSECORAT Other / unclassified 200 ug Inhaled
Subject VELSECORAT Other / unclassified 400 ug Inhaled
Subject VELSECORAT Other / unclassified 1600 ug Inhaled